Karolina Vilval
Consejero General en SEDANA MEDICAL AB .
Cargos activos de Karolina Vilval
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SEDANA MEDICAL AB | Consejero General | 01/08/2022 | - |
| Oncopeptides Incentive AB | Director/Miembro de la Junta | - | - |
Historial de carrera de Karolina Vilval
Antiguos cargos conocidos de Karolina Vilval.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ONCOPEPTIDES AB | Consejero General | 02/03/2020 | 01/08/2022 |
| Gilead Sciences Sweden AB | Consejero General | - | - |
| SWEDISH ORPHAN BIOVITRUM AB | Consejero General | - | - |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Consejero General | - | - |
Formación de Karolina Vilval.
| University of Stockholm | Graduate Degree |
Estadísticas
Internacional
| Suecia | 8 |
Operativa
| General Counsel | 5 |
| Graduate Degree | 1 |
| Director/Board Member | 1 |
Sectorial
| Health Technology | 4 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| SEDANA MEDICAL AB | Health Technology |
| Empresas privadas | 3 |
|---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
| Gilead Sciences Sweden AB | |
| Oncopeptides Incentive AB |
- Bolsa de valores
- Insiders
- Karolina Vilval
- Experiencia
